Related Experiment Videos
IL-10 reduces rat brain injury following focal stroke
P A Spera1, J A Ellison, G Z Feuerstein
1Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA.
Abstract:
The effects of the anti-inflammatory cytokine, IL-10, on brain injury following permanent focal ischemia were determined. Rats subjected to occlusion of the right middle cerebral artery (MCAO) were administered IL-10 (1 microg) centrally into the lateral ventricle 30 min and 3 h post MCAO or systemically into the tail vein (5 or 15 microg/h) starting 30 min post MCAO for 3 h. Brains were removed 24 h later and infarct size was measured. IL-10 administered centrally significantly (P < 0.01) reduced infarct size by 20.7% +/- 6.0 compared to vehicle. Systemic IL-10 administration at 5 and 15 microg/h significantly (P < 0.05) decreased infarct size (40.3% +/- 14.0 and 30.7% +/- 13.7, respectively). These studies indicate that an anti-inflammatory therapeutic approach using IL-10 can provide neuroprotection in ischemic stroke.
Insights
Interleukin-10 (IL-10) administration reduced brain injury in rats after ischemic stroke. This anti-inflammatory cytokine shows potential for neuroprotection in stroke patients.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Ischemic stroke causes significant brain injury.
- Anti-inflammatory cytokines may offer neuroprotection.
- Interleukin-10 (IL-10) is a key anti-inflammatory cytokine.
Purpose of the Study:
- To determine the neuroprotective effects of IL-10 in a rat model of ischemic stroke.
- To evaluate both central and systemic administration of IL-10.
Main Methods:
- Rats underwent middle cerebral artery occlusion (MCAO) to induce focal ischemia.
- IL-10 was administered centrally or systemically at various doses and time points post-MCAO.
- Infarct size was measured 24 hours after MCAO.
Main Results:
- Central IL-10 administration significantly reduced infarct size by 20.7% (P < 0.01).
- Systemic IL-10 administration significantly decreased infarct size by 40.3% and 30.7% at tested doses (P < 0.05).
Conclusions:
- IL-10 demonstrates significant neuroprotective effects against ischemic brain injury.
- Both central and systemic administration of IL-10 are effective in reducing infarct size.
- IL-10 represents a promising therapeutic candidate for treating ischemic stroke.